The Healthcare Paradox: Why Asia’s Investors Should Rethink Their Neglect
There’s a peculiar disconnect in the markets right now, and it’s staring us right in the face: healthcare. Personally, I think this is one of the most undervalued sectors in decades, yet it’s being treated like yesterday’s news. What makes this particularly fascinating is that while the broader market chases the shiny allure of AI and tech, healthcare equities are trading at their steepest discount in over a decade. It’s like everyone’s at a buffet, ignoring the prime rib because they’re too busy fighting over the dessert table.
From my perspective, this isn’t just a valuation anomaly—it’s a psychological misstep. Healthcare has been out of favor for the past two years, largely due to political uncertainty in the U.S., rising interest rates, and the gravitational pull of capital toward AI. But here’s the thing: the fundamentals haven’t changed. Revenue growth is intact, earnings quality remains robust, and innovation is booming. So why the disconnect?
The Sentiment Trap
One thing that immediately stands out is how sentiment can overshadow reality. Healthcare’s underperformance has been persistent, but it’s not because the sector is failing. It’s because investors are fixated on the next big thing. AI is the darling of the moment, and healthcare is the reliable partner everyone’s ignoring. What many people don’t realize is that healthcare isn’t just a defensive play—it’s a growth story. Biopharma M&A is accelerating, medtech is creating new blockbuster markets, and AI is acting as an enabler, not a disruptor.
Take medtech, for example. Robotic surgery systems like Intuitive Surgical’s Da Vinci 5 are revolutionizing how surgeons train and operate. Surgeons used to practice on chickens; now they’re using AI-driven simulations that replicate real-life operating conditions. This isn’t just incremental progress—it’s a paradigm shift. Yet the sector is trading down 16% year-to-date. If you take a step back and think about it, this is a classic case of the market mispricing innovation.
The Valuation Opportunity
Here’s where it gets interesting: healthcare is trading at roughly 17 times forward earnings, compared to 21 times for the S&P 500. That’s a discount well below the long-term average. In my opinion, this is a screaming buy signal. The sector is undervalued, under-owned, and misunderstood. What this really suggests is that investors are so focused on the short-term hype of AI that they’re missing the long-term resilience of healthcare.
A detail that I find especially interesting is the medtech sub-sector. Historically, it traded at 24 to 25 times earnings, but now it’s compressed to around 18 times. This despite delivering 6-9% organic revenue growth and low double-digit earnings-per-share growth. This raises a deeper question: Are investors overreacting to short-term headwinds, like the U.S. government’s decision not to extend Affordable Care Act subsidies? Or is this a once-in-a-decade opportunity to buy innovation at a discount?
Innovation as the Growth Engine
What makes healthcare so compelling is its innovation pipeline. This isn’t just about incremental improvements—it’s about entirely new markets. Take lipoprotein(a), or Lp(a), a genetically determined cholesterol variant that affects one in five people. There’s currently no approved therapy, but companies like Novartis and Amgen are in late-stage trials. This could be a multi-billion-dollar market, and yet it’s barely on investors’ radar.
Similarly, continuous glucose monitoring is projected to grow from $11.7 billion in 2024 to $21.3 billion by 2029. Soft-tissue surgical robotics? Expected to more than double from $8.7 billion to $19.1 billion. These aren’t niche markets—they’re transformative. And yet, healthcare remains structurally underweight in most portfolios.
AI: Enabler, Not Disruptor
There’s a common misconception that AI will disrupt healthcare. In reality, it’s acting as a cost and efficiency lever. Pharma companies are using AI to accelerate drug development, reduce costs, and improve clinical trials. Health insurers are automating invoice processing and contract management. Even in medtech, AI is enhancing surgical systems, not replacing them.
What this really suggests is that healthcare companies are not just adapting to AI—they’re leveraging it to strengthen their competitive advantage. This isn’t disruption; it’s evolution. And it’s happening faster than most investors realize.
The M&A Imperative
Another angle that’s often overlooked is the M&A imperative in biopharma. Patent expirations are looming, and big pharma faces hundreds of billions in revenue at risk over the next four to six years. The solution? Acquisitions. The 20 largest biopharma companies have over $1 trillion in combined financial firepower. This isn’t optional—it’s survival.
Deals like Boston Scientific’s $14.4 billion acquisition of Penumbra and Danaher’s $9.7 billion purchase of Masimo are just the beginning. This wave of consolidation isn’t just about growth—it’s about staying relevant.
Why Asia’s Investors Should Pay Attention
Here’s the thing: healthcare is one of the most defensive and innovation-driven sectors out there. Yet it’s under-owned in most portfolios, especially in Asia. As one multi-family office representative put it, healthcare is “one of the best sectors for our generation because of the domain expertise required.”
Personally, I think this is a wake-up call. The market is overly concentrated in tech and AI, and healthcare offers a logical complement. It’s not just about diversification—it’s about positioning for the future. We don’t know when the tide will turn, but history suggests it will. And when it does, those who acted now will be the ones smiling.
Final Thoughts
Healthcare’s valuation disconnect isn’t just an opportunity—it’s a reminder of how markets can misprice resilience and innovation. From my perspective, this is a sector that’s out of favor but not out of form. The fundamentals are strong, the innovation pipeline is unmatched, and the valuations are compelling.
If you take a step back and think about it, healthcare isn’t just a sector—it’s a necessity. And in a world where necessity meets innovation, there’s always opportunity. The question is: Will Asia’s wealth allocators seize it?
